DWDandan Wang

Dandan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dandan Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Haidong Tian

    College of Life science and Engineering, Lanzhou University of Technology, Lanzhou, China

    1 shared publication
  • Juan Bai

    Department of Oncology, Clinical Medical College &, Affiliated Hospital of Chengdu University, Chengdu, China

    1 shared publication
  • Maoqing Wang

    416 Hospital of Nuclear Industry, Chengdu, China

    1 shared publication
  • Meng Dong

    Department of Radiation Oncology, Division of Thoracic Tumor Multimodality Treatment and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Qingyong Li

    Dongying Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Dongying, China

    1 shared publication
  • Ru Lin

    Shengli Oil Field Central Hospital, Dongying, China

    1 shared publication

Latest Publications

  • Open Access

    Proton beam therapy for craniopharyngioma: a systematic review and meta-analysis

    by Zhi Li, Qingyong Li, Haidong Tian, Maoqing Wang, Ru Lin, Juan Bai, Dandan Wang, Meng Dong

    Craniopharyngioma is a rare and slow-growing benign sellar or parasellar epithelial tumor. The number of patients receiving proton beam therapy (PBT) has increased. This study aimed to systematically evaluate and analyze the comprehensive evidence regarding the safety and efficacy of PBT for craniopharyngioma. We searched four databases: the Cochrane Library, PubMed, Embase, and Web of Science. The period was from their inception to February 16, 2024. Two researchers independently screened the literature and extracted data. Among 486 candidate articles, eight studies were included in our study. Exactly 393 patients with craniopharyngioma underwent PBT in these studies. These studies reported data on survival and toxicity. The median sample size was 42.5 patients. The median age was 9.1–37 years; the female proportion was 48.9%, and the median follow-up time was 29–91.4 months. All patients were treated once daily, five times a week, with a fraction of 1.8 Gy (RBE) per session. The median total dose was 54.0 Gy (RBE). The local control rates at 3 and 5 years in these studies were 99% and 93%, respectively. The overall survival rates at 3 and 5 years in these studies were both 100%. The incidence of acute and late toxicities was mainly grade 1–2. The main late toxicities included vascular and visual toxicities, hypothalamic obesity, endocrinopathy, and panhypopituitarism. PBT for craniopharyngioma, especially in children and adolescents, has shown impressive local control and acceptable acute and late toxicities.


  • Tricuspid Valve Replacement: Mechanical or Biological Prostheses? A Systematic Review and Meta-Analysis

    by Zeyi Cheng, Tingting Fang, Dandan Wang, Yingqiang Guo

    Background: Tricuspid valve replacement (TVR) is seldom performed in cardiac valve surgery, and there currently are no clinical guidelines as to which type of prostheses is better in tricuspid valve position. This meta-analysis was performed to compare the results of mechanical and biological prostheses for TVR. Methods: We searched the Pubmed, Cochrane, and Embase clinical trial databases to collect all related studies published from January 1, 2000 to July 31, 2020. A random-effects model was used to evaluate the odds ratios (OR) and its 95% confidence intervals (CI) of time-to-event related effects of the surgical procedures; every study’s quality was evaluated by the Newcastle-Ottawa Scale (NOS). Results: A total of 13 retrospective studies, including 1453 patients were analyzed. There were no statistically differences between mechanical and biological prostheses with respect to prosthetic valve failure [OR = 0.84, 95% CI(0.54, 1.28), P = .41], bleeding [OR = 0.84, 95% CI(0.54,1.28), P = .41], reoperation [OR = 1.02, 95% CI(0.58,1.78), P = .95], early mortality [OR = 1.35, 95% CI(0.82,2.25), P = .24] and long-time survival [OR = 1.09, 95% CI(0.70, 1.69), P = .70], but a significant difference can be seen in mechanical prostheses with a higher risk of thrombosis [OR = 0.17, 95% CI(0.05, 0.60), P = .006, I2 = 0%]. Conclusions: In tricuspid valve position, mechanical valve prostheses have a higher risk of thrombosis than biological prostheses, but no statistical differences between mechanical and biological prostheses with respect to prosthetic valve failure, bleeding, reoperation, early mortality, and long-term survival. The valve disease and patient’s age and risk factors are the most important considerations in the decision-making process. The more specific conclusion needs to be further proved by large-sample, multi-center, randomized, double-blind and control trials.